US 4,522,918 A · Process for producing monoclonal antibodies reactive with human breast cancer

Abstract

Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.

Claims7

Dependent claims

A process for producing antibodies from hyridoma cultures comprising the steps of

(1) taking splenic lymphocytes of mice previously immunized with membrane-enriched fractions of immunoglobulin-depleted cancer cells;
(2) fusing the lymphocytes with murine myeloma cell line, and
(3) culturing the cell line in an in vitro culture medium or in vivo therefor to produce antibodies, which antibody:
(a) reacts and binds with extracts from human metastatic mammary carcinoma cells from involved livers but not with liver cell extracts;
(b) reacts and binds with at least one of the mammary carcinoma cell lines, BT-20, MCF-7, ZR-75-1, but not with lung, vulva epidermoid or oral epidermoid and not with rhabdomyosarcoma, fibrosarcoma and melanoma;
and
(c) does not react with normal cells derived from breast, skin, lung, bone marrow, kidney, spleen and uterus.

4 more elements

Dependencies are inferred from the claim text.

Process for producing monoclonal antibodies reactive with human breast cancer

Life of this patent

Process for producing monoclonal antibodies reactive with human breast cancer

Life of this patent

Abstract

Claims7